Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Gastrointestinal 3Genitourinary 2Dermatologic 2

Conditions

Melanoma 2Neoplasms 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × tesetaxel × Dermatologic × Clear all
NCT01064713 2018-07-17

Phase II Study of Tesetaxel in Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed
17 enrolled 5 charts
Dermatologic

Melanoma, Neoplasms

NCT01092585 2011-11-08

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Genta Incorporated

Phase 2 Unknown
27 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡